Harness Therapeutics is a biotechnology company focused on the development of next generation therapeutics for the treatment of neurodegenerative diseases, with a lead programme in Huntington’s Disease. Focussing on neurodegeneration targets with strong biology and genetic validation, Harness Therapeutics utilises its deep understanding of RNA biology and post-transcriptional regulation to enable drugging with oligonucleotide based drugs to upregulate protein expression. Harness Therapeutics has assembled a world-class team focused on the mission of building the most efficient physiological protein upregulation platform. This includes extensive RNA biology and bioinformatics expertise, specialist analytics capabilities and neurological cell models. Harness Therapeutics’ unique target-centric approach generates multiple orthogonal upregulation strategies combined with a detailed understanding of target biology to develop new medicines that can treat the underlying causes of neurodegenerative diseases. Harness Therapeutics is based in Cambridge, UK, and is backed by leading life science investors – Takeda Ventures, The Dementia Discovery Fund and Epidarex Capital.